Jazz Pharmaceuticals' And Zymeworks' Ziihera Success: A Pleasant Surprise [Seeking Alpha]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Seeking Alpha
Ziihera in combination with chemotherapy and in combination with Tevimbra and chemotherapy outperformed trastuzumab plus chemotherapy, and the triple combination achieved statistically significant overall survival benefit. The GEA indication represents a $2 billion+ a year opportunity for JAZZ and a $300 million opportunity for BeOne, and ZYME stands to benefit by receiving royalties from both partners. The caveat is that these are topline results with no efficacy or safety data in the press release, and there is a risk of the detailed data disappointing next year. This is the first significant market opportunity for Ziihera, and additional trials are ongoing or planned. mouu007/iStock via Getty Images Shares of Jazz Pharmaceuticals plc JAZZ ) and Zymeworks Inc. ZYME ) are up today as the two companies announced positive phase 3 results of Ziihera (zanidatamab) from the HERIZON-GEA trial in patients More on my IG service I publish my best ideas and top coverage on the G
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual MeetingPR Newswire
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! FinaYahoo! Fina
- Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers SymposiumPR Newswire
JAZZ
Earnings
- 11/5/25 - Beat
JAZZ
Sec Filings
- 12/5/25 - Form 144
- 12/4/25 - Form 4
- 12/1/25 - Form 144
- JAZZ's page on the SEC website